Chimerix (CMRX) Aktie Kurs
Chimerix Kurs
Omsætningen i Chimerix er faldet med 13,9 % om året de seneste 14 år til 212.000,00 USD. For Chimerix er nettoavance på -41.692,0 % ned i forhold til -784,2 % for et par år siden. Konsensus 12-måneders kursmål for Chimerix er 8,72 USD, cirka over kursen med 2,1 %. Af 11 analytikere anbefaler 10 køb — den samlede vurdering er Køb.
Chimerix aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Chimerix aktie og aktieanalyse
Hyppigt stillede spørgsmål om Chimerix-aktien
Chimerix Inc. operates with a business model focused on the development and commercialization of innovative antiviral therapeutics. The company aims to address unmet medical needs and improve patients' lives through the discovery, research, and development of novel antiviral medications. Chimerix Inc. primarily focuses on developing oral nucleotide analogs that target viral replication and replication pathways, aiming to provide effective treatments for various viral infections. With its commitment to advancing medical science, Chimerix Inc. leverages its expertise to create valuable pharmaceutical solutions, contributing to the advancement of antiviral therapeutics.
Chimerix Inc primarily operates in the biotechnology and pharmaceutical industries.
The main competitors of Chimerix Inc in the market include pharmaceutical companies such as Gilead Sciences, Merck & Co., and GlaxoSmithKline.
Chimerix Inc is a pharmaceutical company based in Durham, North Carolina. Founded in 2002, the company primarily focuses on the development and commercialization of innovative antiviral therapeutics. Chimerix has a rich history in the field of antiviral research and has made significant contributions to the medical community. The company's mission is to discover, develop, and deliver novel medicines to improve the lives of patients suffering from life-threatening diseases. With a dedicated team of scientists and researchers, Chimerix continues to advance its pipeline of antiviral drugs, providing hope for patients worldwide.
Chimerix Inc has achieved significant milestones throughout its history. One notable achievement was the successful completion of Phase 3 clinical trials for its antiviral drug, brincidofovir. This marked a crucial milestone in the company's efforts to develop an effective treatment for viral infections, including cytomegalovirus. Additionally, Chimerix Inc has secured multiple partnerships and collaborations with renowned healthcare organizations and research institutions. These partnerships have paved the way for further advancements in Chimerix's drug development pipeline and enhanced its potential to address unmet medical needs. Chimerix Inc continues to strive for further milestones and innovations in the field of antiviral therapeutics.
Chimerix Inc is primarily present in the United States.
Chimerix Inc is a biopharmaceutical company that is committed to improving the lives of patients suffering from life-threatening diseases. Their corporate philosophy revolves around innovation, collaboration, and patient-centered care. Chimerix Inc values scientific excellence, integrity, and transparency in all aspects of their operations. They strive to develop novel antiviral therapies to address unmet medical needs. With a dedicated team of experts, Chimerix Inc focuses on delivering innovative solutions that can make a significant impact in the medical field. This commitment to patients, scientific advancement, and ethical practices defines Chimerix Inc and sets them apart in the biopharmaceutical industry.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 8,71 USD for Chimerix-aktien (median: 8,72 USD), svarende til +2,0 % i forhold til seneste kurs. Konsensus bygger på 11 analytikervurderinger.
11 analytikere vurderer i øjeblikket Chimerix-aktien: 7 anbefaler køb, 4 hold og 0 salg. For 2026 forventer analytikere, at Chimerix genererer omsætning på 38,60 Mio. USD og indtjening pr. aktie på -0,81 USD.
Omregnet til den aktuelle valutakurs handles Chimerix-aktien til 7,60 EUR (8,54 USD).
Chimerix-aktien (CMRX) er noteret på 5 børser, herunder: NASDAQ (CMRX), SIX (Zürich) (CXF.SW), Frankfurt (CXF.F), München (CXF.MU), Düsseldorf (CXF.DU).
Chimerix Inc is a US biotech company specializing in the development of antiviral and immunoncology therapeutics. It was founded in 2000 and is headquartered in Durham, North Carolina. The company's business model focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases and cancer. Chimerix operates in two main areas: infectious diseases and cancer. In infectious diseases, its leading product is Brincidofovir (BCV) for the treatment of life-threatening virus infections such as cytomegalovirus (CMV) and adenovirus infections. In cancer therapy, Chimerix has multiple products in its pipeline that aim to activate the immune system to fight tumors. The company collaborates with leading academic and clinical research institutions and utilizes various business models to market its products, including partnerships with government-funded research programs and multinational pharmaceutical companies. Overall, Chimerix has a promising pipeline of products in clinical studies and is well-positioned to improve global patient care.
forventet-omsætningen for Chimerix er 38,60 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Chimerix er -73,55 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Chimerix er i øjeblikket -10,48. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Chimerix-aktien.
Pris-til-salgs-forholdet (P/S) for Chimerix er i øjeblikket 19,97. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Chimerix-aktien.
AlleAktien-kvalitetsscore for Chimerix er 2/10.
ISIN for Chimerix er US16934W1062. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Chimerix er A1T65B. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Chimerix er CMRX. Tickersymbolet bruges til at handle Chimerix-aktier på børsen.
Chimerix aktie
Chimerix Peer Group
Chimerix Ticker
Chimerix FIGI
Alle fundamentale data om Chimerix i deep dive
Vores aktieanalyse af Chimerix-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Chimerix. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: